New Antibody Treatment for Pancreatic Cancer
Researchers have created a novel antibody treatment aimed at helping the immune system identify and combat pancreatic cancer. Pancreatic cancer cells have a sneaky way of using sugary disguises to evade detection by the immune system.
While most cancer immunotherapies typically target specific proteins or genes, this innovative treatment focuses on sugars present on the cell surface. By blocking these sugars, the treatment enables immune cells to recognize and attack the cancer more effectively, according to researchers from Northwestern University in Chicago.
Cancer Vaccines and Tumor Recurrence
Mohamed Abdel Mohsen, an associate professor at Northwestern University’s Feinberg School of Medicine, expressed surprise at how a single sugar—sialic acid—could mislead immune cells so effectively. He explained, “When a tumor covers itself in this molecule, it basically flips an immune ‘off switch,’ signaling immune cells to think it’s just a normal, healthy cell.”
Studies conducted on mice indicated that this treatment successfully blocked the sugar signal, resulting in immune cells being “woken up” and cancer growth slowing down. The antibody-treated tumors grew considerably slower compared to those that were not treated.
Potential for Human Testing
The researchers believe these findings could lead to clinical trials in humans, potentially in combination with chemotherapy or existing immunotherapies. These results were published in the journal Cancer Research on November 3.
“Although this is early-stage preclinical research and not a treatment yet, it opens up new immune targets for pancreatic cancer,” noted Abdel Mohsen.
Heloisa P. Soares, MD, from the Huntsman Cancer Institute, shared her thoughts on the study, describing it as “encouraging” since it introduces a new approach for helping the immune system recognize and fight pancreatic cancer. She said it was surprising to find that a protein, which typically aids cell adhesion, is co-opted by pancreatic cancer as a sort of covert “don’t attack” signal. “Blocking this signal allowed immune cells to re-engage and attack tumors more effectively, suggesting a promising new direction for treatment.”
The Challenge of Pancreatic Cancer
Pancreatic cancer remains one of the most lethal forms of cancer, largely due to its late diagnosis. With only about a 13% five-year survival rate, treatment options are limited. Unlike many cancers, pancreatic cancer often shows minimal response to immunotherapy.
Dr. Mark Siegel, a FOX News senior medical analyst, explained that the cancer is frequently diagnosed at an advanced stage because it can be asymptomatic and hidden deep within the body. Additionally, pancreatic cancer has fewer reliable immune targets and mutations, making treatment particularly challenging.
The researchers acknowledged some limitations in their study, noting that it has only been conducted on animals to date with no human data available yet. “Animal models can’t fully capture the complexities of human pancreatic cancer,” the lead researcher commented, emphasizing that tumors often have multiple ways to evade treatment. Thus, this strategy might need to be part of a broader approach.
The researchers predict it could take around five years for this treatment to potentially become available to patients, contingent upon successful human clinical trials.
In summary, while this research is a promising step forward, it won’t transform treatment protocols overnight. Continued funding and active participation in clinical trials will be crucial to advance this progress.
This research was partially supported by the National Institutes of Health.
